Septic arthritis due to Roseomonas mucosa in a rheumatoid arthritis patient receiving infliximab therapy.
We report a case of septic arthritis due to Roseomonas mucosa in a rheumatoid arthritis patient receiving infliximab therapy. This is the first report of septic arthritis due to R. mucosa, and infliximab therapy might be a predisposing factor because this infection was never reported in the pre-anti-tumor necrosis factor alpha therapy period.
Sipsas
Nikolaos V
NV
Pathophysiology Department, Laikon General Hospital and Medical School, National and Kapodistrian University of Athens, 11527, Athens, Greece.
Papaparaskevas
Joseph
J
Stefanou
Ioanna
I
Kalatzis
Konstantinos
K
Vlachoyiannopoulos
Panayiotis
P
Avlamis
Athina
A
D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects; D018501:Antirheumatic Agents / Q000009:adverse effects; D001170:Arthritis, Infectious / Q000276:immunology / Q000382:microbiology*; D016905:Gram-Negative Bacterial Infections / Q000276:immunology / Q000382:microbiology*; D006801:Humans; D016867:Immunocompromised Host; D000069285:Infliximab; D008297:Male; D042082:Methylobacteriaceae / Q000235:genetics; D008969:Molecular Sequence Data
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D000069285:Infliximab